Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?

Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?

ABSTRACT Background: Cyclophosphamide plus thalidomide as induction for multiple myeloma patients eligible for autologous stem cell transplantation may be a limiting factor for cell mobilization. The minimum acceptable mobilized peripheral blood stem cell count to prevent deleterious effects during...

Full description

Bibliographic Details
Main Authors:	Edvan de Queiroz Crusoe, Fabiana Higashi, Gracia Aparecida Martinez, José Carlos Barros, Marcelo Bellesso, Marina Rossato, Ana Cinira F. Marret, Carlos Sérgio Chiattone, Vania Tietsch de Moraes Hungria
Format:	Article
Language:	English
Published:	Elsevier
Series:	Revista Brasileira de Hematologia e Hemoterapia
Subjects:	Bone marrow transplantation Multiple myeloma Granulocyte-colony stimulating factor Cyclophosphamide
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000400302&lng=en&tlng=en

Similar Items

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
by: Edvan De Queiroz Crusoe, et al.
Published: (2020-04-01)

Influence of Modified Fucoidan and Related Sulfated Oligosaccharides on Hematopoiesis in Cyclophosphamide-Induced Mice
by: Natalia Yu. Anisimova, et al.
Published: (2018-09-01)

Comparison of cyclophosphamide–thalidomide–dexamethasone to bortezomib–cyclophosphamide–dexamethasone as induction therapy for multiple myeloma patients in Brazil
by: Suelen Vigolo, et al.
Published: (2017-09-01)

Fucoidan and Fucosylated Chondroitin Sulfate Stimulate Hematopoiesis in Cyclophosphamide-Induced Mice
by: Natalia Anisimova, et al.
Published: (2017-09-01)

Dexamethasone- cyclophosphamide pulse in collagen vascular diseases: An observation
by: Sudip Das, et al.
Published: (2011-01-01)

Treatment of Paraquat Poisoning with Cyclophosphamide / Dexamethasone Combination : The First Two Years Experience at Siriraj Hospital
by: Summon Chomchai, et al.
Published: (2004-04-01)

Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group
by: Reza Safaee, et al.
Published: (2012-07-01)

Membrane permeability properties of human granulocytes
by: Vian, Alexander M.
Published: (2013)

Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?
by: Afonso Celso Vigorito

Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
by: Edvan de Queiroz Crusoe, et al.
Published: (2014-01-01)

Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna
by: M.M. Morais, et al.
Published: (1999-10-01)

A comparative study to evaluate the efficacy and cost of rituximab versus dexamethasone cyclophosphamide pulse in patients of pemphigus vulgaris
by: Sudip Das, et al.
Published: (2021-01-01)

Chemomobilization with cyclophosphamide and filgrastim in multiple myeloma patients following lenalidomide treatment
by: Gerfen, Ashlee
Published: (2012)

PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS
by: E.Q. Crusoé, et al.
Published: (2020-11-01)

Comparative retrospective evaluation of efficacy of rituximab therapy with dexamethasone cyclophosphamide pulse therapy in patients of pemphigus vulgaris at a tertiary care hospital
by: Preema Sinha, et al.
Published: (2020-01-01)

What Is the Evolutionary Fingerprint in Neutrophil Granulocytes?
by: Leonie Fingerhut, et al.
Published: (2020-06-01)

Evaluation of granulocytes reposition and appearance of the adverse effects produced by the stimulating factors of granulocytic colonies.
by: Gracia Solera Camarasa, et al.
Published: (2017-08-01)

Clinical efficacy of cyclophosphamide in treatment of primary sclerosing cholangitis
by: CHENG Peng
Published: (2013-12-01)

Granulocytic sarcoma of finger: a case report
by: Aysin Purbager, et al.
Published: (2016-03-01)

Granulocyte-stimulating activity of the anticoagulant warfarin in rats
by: Kataranovski Milena, et al.
Published: (2007-01-01)

PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS
by: E.Q. Crusoé, et al.
Published: (2020-11-01)

Study on Hemostimulating Properties of Granulocyte-Macrophage Colony Stimulating Factor
by: G. G. Shimina, et al.
Published: (2020-12-01)

Apoptosis of Eosinophil Granulocytes
by: Martina Zustakova, et al.
Published: (2020-12-01)

Chemomobilization with Cyclophosphamide and Filgrastim in Multiple Myeloma Patients Following Lenalidomide Treatment
by: Gerfen, Ashlee, et al.
Published: (2012)

Cyclophosphamide-induced cancers in pemphigus patients –A report of three cases
by: Vikrant Abhay Saoji
Published: (2020-01-01)

Premature ovarian failure in systemic lupus erythematosus patients: is it related to cyclophosphamide treatment?
by: Rasha M Ghaleb, et al.
Published: (2019-01-01)

Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis
by: Serika D Naicker, et al.
Published: (2021-01-01)

A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia
by: Mark Clemons, et al.
Published: (2021-08-01)

Toxic effects of different doses of cyclophosphamide on the reproductive parameters of male mice
by: Tatiane Yumi Nakamura Kanno, et al.
Published: (2009-06-01)

Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis
by: Masoud Etemadifar, et al.
Published: (2020-02-01)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
by: Priscilla Cury de Camargo Cury, et al.
Published: (2020-04-01)

Clinical evaluation of cyclophosphamide therapy in patients with myasthenia gravis and thymoma
by: Ling HUANG, et al.
Published: (2014-10-01)

Follicle Loss and Apoptosis in Cyclophosphamide-Treated Mice: What’s the Matter?
by: Xiu-Ying Chen, et al.
Published: (2016-05-01)

Managing a side effect: Cyclophosphamide-induced hemorrhagic cystitis
by: Bhavana Ravindra Doshi, et al.
Published: (2019-01-01)

Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review
by: Kaian Amorim Teles, et al.

Cytoprotective Effects of Carvacrol on Cyclophosphamide Induced Hematoxicity
by: Mustafa CENGİZ, et al.
Published: (2018-06-01)

Ethyl Pyruvate Ameliorates The Damage Induced by Cyclophosphamide on Adult Mice Testes
by: Zahra Bakhtiary, et al.
Published: (2016-04-01)

Alternative-day combined granulocyte and platelet transfusions for patients with acute myeloid leukaemia
by: Ford, J. M.
Published: (1981)

Granulocytes Acquire Antiapoptosis Activity and Promote Tumor Growth during Tumor Progress
by: Han Li, et al.
Published: (2021-03-01)

Ameliorative action of farnesol on cyclophosphamide induced toxicity in mice
by: Atefeh Araghi, et al.
Published: (2018-01-01)